The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Identifying and addressing the underuse of hydroxyurea in SCD
In this video, Alexandra Power-Hays, MD, Cincinnati Children’s, Cincinnati, OH, gives an overview of a session held at ASH 2023 which addressed the underuse of hydroxyurea in sickle cell disease (SCD). Dr Power-Hays explains that there are certain stigmas and biases associated with this agent which may impact its use in clinical practice. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
